Phaseline

Targets › TLR3

TLR3 (Toll-like receptor 3): drug programs, companies and trials

10 programs from 9 companies in 11 trials: 7 Phase 1, 4 Phase 2; Oncology; next expected readout Dec 2026.

Transmembrane receptor that functions as a pattern recognition receptor recognizing double-stranded RNA (dsRNA), a sign of viral infection, to induce innate immune responses via downstream signaling pathways. Acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. (UniProt, O15455)

Open in Phaseline: the race on TLR3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ashutosh Kumar TewariPoly-ICLC (Hiltonol®)
Toll-like receptor 3 (TLR3) agonist; synthetic double-stranded RNA analog that activates i
TLR3Phase 2Prostate Cancer Patients on Active Surveillance; Prostate CancerDec 2026
James FelkerHLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
Peptide vaccine with TLR3 agonist adjuvant targeting glioma-associated antigens
TLR3Phase 2Low Grade GliomaJan 2027
Roswell Park Cancer InstituteRintatolimod
Toll-like receptor 3 agonist
TLR3Phase 2Prostate AdenocarcinomaApr 2027
RocheAutogene Cevumeran
TLR3 agonist
TLR3Phase 2Muscle-invasive Urothelial CarcinomaNov 2027
Joachim Aerts, MD PhDRintatolimod
Toll-like receptor 3 agonist
TLR3Phase 1Metastatic Pancreatic CancerDec 2026
Robert EdwardsRintatolimod
Toll-like receptor 3 agonist
TLR3Phase 1Ovarian Cancer RecurrentJan 2027
Washington University School of MedicinePoly-ICLC
Toll-like receptor 3 (TLR3) agonist - adjuvant
TLR3Phase 1Pancreas CancerOct 2027
Finn, Olivera, PhDHiltonol® (POLY-ICLC)
Synthetic dsRNA viral mimic and toll-like receptor 3 (TLR3) agonist; host-defense activato
TLR3Phase 1Ductal Carcinoma in SituFeb 2028
Adilia HormigoPoly-ICLC (Hiltonol®)
Toll-like receptor 3 (TLR3) agonist and RIG-I-like receptor agonist - immune adjuvant
TLR3, RIG1Phase 1GlioblastomaMay 2029
Washington University School of MedicinePoly ICLC
Toll-like receptor 3 (TLR3) agonist / innate immune activator
TLR3Phase 1Muscle-Invasive Bladder CarcinomaJan 2030

Conditions

Low Grade Glioma (1) Prostate Adenocarcinoma (1) Ductal Carcinoma in Situ (1) Muscle-Invasive Bladder Carcinoma (1) Prostate Cancer Patients on Active Surveillance (1) Prostate Cancer (1) Glioblastoma (1) Muscle-invasive Urothelial Carcinoma (1) Pancreas Cancer (1) Ovarian Cancer Recurrent (1) Metastatic Pancreatic Cancer (1)

Modalities

mixed (8), protein or peptide (1), small molecule (1)

Companies

Washington University School of Medicine (2) James Felker (1) Roswell Park Cancer Institute (1) Finn, Olivera, PhD (1) Ashutosh Kumar Tewari (1) Adilia Hormigo (1) Roche (1) Robert Edwards (1) Joachim Aerts, MD PhD (1)

Related targets

RIG1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.